Teriparatide transdermal - TransPharma

Drug Profile

Teriparatide transdermal - TransPharma

Alternative Names: hPTH (1-34); ViaDerm-hPTH (1-34); ViaDor-hPTH (1-34)

Latest Information Update: 05 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TransPharma Medical
  • Developer Eli Lilly; TransPharma Medical
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 21 Oct 2013 Biomarkers information updated
  • 30 Sep 2011 Eli Lilly completes a phase II trial in Osteoporosis in Argentina, Estonia, Hungary, Mexico and Romania (NCT01011556)
  • 11 May 2011 Eli Lilly completes a Phase-I clinical trial in Osteoporosis in USA, Germany and the United Kingdom (NCT01250145)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top